Sortera Bio announces appointment of David Llewellyn as Chair of the Board of Directors
Cambridge, UK – 4th November 2025 – Sortera Bio, a pioneering biotechnology company leveraging Deep Screening to bring next generation biologics to partners, has today announced the appointment of Dr David Llewellyn as its Chair to lead the company through its next phase of growth. Dr Llewellyn replaces Robert Tansley, who is stepping down as Executive Chair and will remain on the board as an investor director.
Dr Llewellyn brings exceptional leadership experience and industry expertise to Sortera at a crucial moment for the company as it prepares for its next funding round and accelerates the commercialisation of its Deep Screening technology. As CEO and co-founder of DJS Antibodies, Dr Llewellyn helped the company develop a groundbreaking antibody discovery platform and took it from inception through to its successful acquisition by AbbVie. Dr Llewellyn’s experience in steering DJS Antibodies positions him well to provide strategic guidance to Sortera’s management team as they scale operations and expand partnerships.
Beyond executive experience, David has a strong background in evolutionary immunology, antibody discovery and development. He holds a PhD in Clinical Medicine from the University of Oxford, where he studied as a Rhodes Scholar. His commitment to positive impact extends beyond his biotechnology as co-founder of Beyond Equality, an organisation dedicated to promoting positive masculinity and gender equality.
“I’m excited by the addition of David to the team at Sortera. His recent experiences in taking DJS, a platform antibody company, from inception to success are highly relevant for Sortera as we progress through our next phase of growth. I look forward to learning from David as we leverage Deep Screening for developing next generation biologics” said Ben Porebski, CEO/CTO Sortera Bio.
“Sortera’s technology is the biggest leap in antibody discovery since phage display with the potential to revolutionise the space. I have little doubt that Deep Screening will be central to the discovery of the next generation of life saving biologics and it’s an absolute pleasure to work with the team to make that a reality” said David Llewellyn. We are excited to have David on board and look forward to leveraging his expertise and passion to drive Sortera’s continued growth and innovation.
ENDS
About Sortera Bio
Sortera Bio Ltd is a Cambridge UK-based biotechnology company based on intellectual property developed at the MRC Laboratory of Molecular Biology. Sortera is focused on accelerating the discovery of biologics via its proprietary Deep Screening platform and is dedicated to delivering transformative solutions in biologics discovery to meet the needs of patients worldwide.
Contact: hello@sortera.bio
https://sortera.bio
Follow Sortera Bio on LinkedIn